Browse the evidence

Obesity has reached an epidemic scope in the United States and is a significant public health concern.

Healthcare practitioners should prioritize addressing obesity as a critical health issue.

Plastic surgery in patients with obesity is associated with higher complication rates before and after weight loss.

Surgeons should be aware of the increased risks when operating on obese patients.

The cost needed to treat for 1% of weight loss with semaglutide and tirzepatide is $1845 and $985, respectively.

Healthcare providers should be aware of the cost implications when prescribing these medications.

Clinical trials of tirzepatide have demonstrated cardiovascular safety in high-risk patients.

Tirzepatide may be considered safe for use in patients at high cardiovascular risk.

The cardiovascular benefits of dual GLP-1/GIP receptor agonists like tirzepatide remain uncertain.

Further research is needed to clarify the cardiovascular benefits of tirzepatide.

Bariatric surgery cannot completely eliminate the possibility of weight regain and inadequate weight loss.

Patients should be informed about the potential for weight regain after surgery.

Changes in lean mass (LM) are not significantly associated with the risk of kidney outcomes (adjusted HR 0.78, 95% CI 0.58-1.06) in participants with overweight/obesity and T2DM.

Practitioners may not need to prioritize lean mass changes for kidney health in T2DM patients.

There is no evidence that the weight loss can be sustained over time.

Practitioners should be cautious about recommending low-carbohydrate diets for long-term weight loss.

About two-thirds of the US population can be classified as overweight or obese based on body mass index.

Practitioners should be aware of the high prevalence of obesity and overweight in the US population.

A semisupervised high-intensity interval training (HIT) intervention did not increase menstrual frequency in women with polycystic ovary syndrome (PCOS).

Practitioners should note that HIT may not be effective for improving menstrual frequency in women with PCOS.

The postoperative incidence of beneficial effects and complications from RYGB varies across patient subgroups with different preoperative characteristics.

Individualized assessment of patients is crucial to optimize RYGB outcomes and minimize complications.

Severe adverse effects with GLP-1 RA use are not uncommon and warrant further close monitoring.

Practitioners should closely monitor patients for severe adverse effects when initiating GLP-1 RA therapy.

There is an ongoing debate over the role of pharmacotherapy versus interventional approaches in treating obesity and MASLD in liver transplantation.

Clinicians should stay informed about evolving treatment options for obesity and MASLD.

Experience with GLP-1 agonists in patients with obesity and inflammatory skin diseases is currently scarce.

Further research is needed to establish the efficacy and safety of GLP-1 agonists in this specific population.

The use of semaglutide in patients with previous intake of other AOMs was associated with inferior weight loss outcomes.

Healthcare providers should be cautious when prescribing semaglutide to patients with a history of AOM use, as they may not achieve optimal weight loss.

There is a need for a dedicated trial to examine the benefits of semaglutide in type 1 diabetes.

Further research is warranted to validate the effects of semaglutide in type 1 diabetes.

Tirzepatide has a generally safe profile with possible mild-to-moderate gastrointestinal side effects.

Healthcare providers should monitor patients for gastrointestinal side effects when prescribing tirzepatide.

Neither chia flour nor whey protein supplementation elicited an enhanced effect on fat-free mass (FFM) and strength gains after an 8-week resistance training program.

Supplementing with chia flour or whey protein does not provide additional benefits for body composition or strength in young men already consuming a high protein diet.

Global consumption of ultra-processed foods (UPFs) has increased dramatically.

Practitioners should be aware of the rising trend in UPF consumption.

No additional benefits were observed for ∑MT.

Practitioners should note that increasing volume may not benefit all measures of training outcomes.

In this specific OIP only a small number of obese patients reduced their bodyweight, even though the examined parameters improved significantly.

Despite improvements in health metrics, the program may need to enhance its focus on actual weight loss.

No significant differences were found in cardiorespiratory measures or VO2max as a result of the plyometric training.

Improvements in running economy may occur without changes in traditional cardiorespiratory metrics.

Current public health recommendations for larger changes have not been successful in preventing obesity.

Practitioners should consider advocating for smaller, more achievable lifestyle changes.

There are inadequacies in the measures used to qualify obesity.

Practitioners should be aware of the limitations in current obesity measures when assessing health risks.